Latest updates for Amgn
Fresh curated links around AMGN are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Amgen's Growth Engine Is Just Getting Started
- Amgen: A Biotech Giant's Path to Recovery and Growth
- Argenx
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Amgen: A Biotech Giant's Path to Recovery and Growth
Join us as we dissect Amgen's stock performance and management strategies. Is this biotech giant poised for growth, or is it facing significant challenges ahead?
Argenx
Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Argenx
Argenx Anonymous (not verified) Sat, 05/30/2026 - 14:41 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
The fall of Amgen
The fall of Amgen Anonymous (not verified) Sun, 05/17/2026 - 08:33 field_thread_url https://cafepharma.com/boards/threads/the-fall-of-amgen.709419/...
How Safe Is Amgen's Dividend?
Near-term headwinds could sink the stock, but there is more to the story.
The fall of Amgen
The fall of Amgen Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/the-fall-of-amgen.709419/...
argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System
<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>
Apellis Acquisition
Apellis Acquisition Anonymous (not verified) Mon, 06/22/2026 - 00:00 field_thread_url https://cafepharma.com/boards/threads/apellis-acquisition.715869/...
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.
AMUU: Bull 2x Of AMD In The Phase Of Most Extreme Momentum
Apellis Acquisition
Apellis Acquisition Anonymous (not verified) Sat, 07/11/2026 - 09:12 field_thread_url https://cafepharma.com/boards/threads/apellis-acquisition.715869/...
Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review
Rival pharmaceutical companies that squared off at the U.S. Supreme Court over antibody patents have jointly asked the full Federal Circuit to review an unrelated panel decision re...
ANC
ANC Anonymous (not verified) Thu, 06/04/2026 - 17:44 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare H...
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>
Genmab
Genmab Anonymous (not verified) Thu, 07/02/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Genmab
Genmab Anonymous (not verified) Mon, 07/13/2026 - 12:14 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.